Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PYPD Stock Summary
In the News
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Raghuram Selvaraju - H.C.
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York.
PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Conference Call Participants Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. [Operator Instructions].
PolyPid to Participate in Upcoming Investor Conferences
PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:
PolyPid Ltd (PYPD) Q4 2022 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q4 2022 Earnings Conference Call February 8, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon Folkes - Cantor Fitzgerald Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions].
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PYPD Financial details
PYPD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 10.72 | -57.3 | -65.24 | -55.16 | -16.99 | |
Operating cash flow per share | -39.16 | -35.03 | -51.9 | -47.89 | -12.27 | |
Free cash flow per share | -41.15 | -36.94 | -56.69 | -50.36 | -12.41 | |
Cash per share | 60.07 | 72.14 | 51.6 | 17.58 | 3.99 | |
Book value per share | 69.8 | 118.05 | 58.06 | 8.18 | -1.49 | |
Tangible book value per share | 69.8 | 118.05 | 58.06 | 8.18 | -1.49 | |
Share holders equity per share | 69.8 | 118.05 | 58.06 | 8.18 | -1.49 | |
Interest debt per share | 0.03 | 0.03 | 0 | 20.59 | 9 | |
Market cap | 252.63M | 183.1M | 107.46M | 15M | 5.34M | |
Enterprise value | 248.7M | 178.78M | 97.64M | 20.18M | 11.51M | |
P/E ratio | 53.19 | -5.18 | -2.64 | -0.38 | -0.22 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -14.55 | -8.48 | -3.32 | -0.44 | -0.31 | |
PFCF ratio | -13.85 | -8.04 | -3.04 | -0.42 | -0.31 | |
P/B Ratio | 8.17 | 2.52 | 2.97 | 2.56 | -2.55 | |
PTB ratio | 8.17 | 2.52 | 2.97 | 2.56 | -2.55 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.51 | -6.8 | -2.28 | -0.52 | -0.55 | |
EV to operating cash flow | -14.33 | -8.28 | -3.01 | -0.59 | -0.67 | |
EV to free cash flow | -13.64 | -7.85 | -2.76 | -0.56 | -0.66 | |
Earnings yield | 0.02 | -0.19 | -0.38 | -2.63 | -4.47 | |
Free cash flow yield | -0.07 | -0.12 | -0.33 | -2.4 | -3.27 | |
Debt to equity | 0 | 0 | 0 | 2.34 | -5.21 | |
Debt to assets | 0 | 0 | 0 | 0.53 | 0.71 | |
Net debt to EBITDA | 0.13 | 0.16 | 0.23 | -0.13 | -0.29 | |
Current ratio | 10.63 | 16.54 | 4.46 | 1.64 | 0.83 | |
Interest coverage | -1.24K | -1.55K | 0 | -38.01 | -13.36 | |
Income quality | 2.51 | 0.59 | 0.76 | 0.87 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.05 | 0.09 | 0.05 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.93 | -1.16 | -2.68 | -1.03 | -0.11 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 129.73 | 390.12 | 291.93 | 100.75 | 23.89 | |
ROIC | 0.41 | -0.35 | -1.14 | -1.79 | -2.37 | |
Return on tangible assets | 0.14 | -0.47 | -0.92 | -1.52 | -1.55 | |
Graham Net | 54.15 | 67.86 | 20.89 | -10.03 | -8.44 | |
Working capital | 24.84M | 44.72M | 27.01M | 5.55M | -1.22M | |
Tangible asset value | 30.94M | 72.78M | 36.23M | 5.86M | -2.1M | |
Net current asset value | 24.58M | 44.53M | 26.81M | -5.92M | -11.4M | |
Invested capital | 0 | 0 | 0 | 2.34 | -5.21 | |
Average receivables | 21K | 90.5K | 128.5K | 208K | 149K | |
Average payables | 1.36M | 1.28M | 2.56M | 2.64M | 956.5K | |
Average inventory | 175.5K | 498.5K | -10.93M | -11.14M | 106.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 609.36 | 351.29 | 1.35K | 241.99 | 154.65 | |
Days of inventory on hand | 135.29 | 232.99 | -7.35K | 45.17 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.6 | 1.04 | 0.27 | 1.51 | 2.36 | |
Inventory turnover | 2.7 | 1.57 | -0.05 | 8.08 | 0 | |
ROE | 0.15 | -0.49 | -1.12 | -6.74 | 11.39 | |
Capex per share | -1.98 | -1.91 | -4.8 | -2.47 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -9.97 | -8.47 | -3.95 | -3.4 | -3.84 | |
Operating cash flow per share | -48.16 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -47.94 | 0 | 0 | 0 | 0 | |
Cash per share | 19.22 | 18.74 | 10.21 | 6.15 | 3.39 | |
Book value per share | 8.94 | 15.92 | 5.64 | 2.14 | -1.27 | |
Tangible book value per share | 8.94 | 15.92 | 5.64 | 2.14 | -1.27 | |
Share holders equity per share | 8.94 | 15.92 | 5.64 | 2.14 | -1.27 | |
Interest debt per share | 21.11 | 34.43 | 8.24 | 7.37 | 6.82 | |
Market cap | 13.72M | 9.89M | 16.2M | 7.44M | 6.28M | |
Enterprise value | 18.9M | 16.36M | 24.98M | 17.93M | 12.45M | |
P/E ratio | -0.52 | -0.41 | -0.69 | -0.33 | -0.25 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.43 | 0 | 0 | 0 | 0 | |
PFCF ratio | -0.44 | 0 | 0 | 0 | 0 | |
P/B Ratio | 2.34 | 0.87 | 1.94 | 2.1 | -3 | |
PTB ratio | 2.34 | 0.87 | 1.94 | 2.1 | -3 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.86 | -2.83 | -4.29 | -3.41 | -2.08 | |
EV to operating cash flow | -0.6 | 0 | 0 | 0 | 0 | |
EV to free cash flow | -0.6 | 0 | 0 | 0 | 0 | |
Earnings yield | -0.48 | -0.61 | -0.36 | -0.75 | -1.01 | |
Free cash flow yield | -2.29 | 0 | 0 | 0 | 0 | |
Debt to equity | 2.34 | 1.13 | 1.46 | 3.35 | -5.21 | |
Debt to assets | 0.53 | 0.41 | 0.46 | 0.57 | 0.71 | |
Net debt to EBITDA | -0.78 | -1.12 | -1.51 | -1.99 | -1.03 | |
Current ratio | 1.64 | 2.75 | 2.89 | 1.89 | 0.83 | |
Interest coverage | -66.12 | 0.49 | -831.43 | -16.49 | -17.24 | |
Income quality | 4.83 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.55 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 44.8 | 55.07 | 22.38 | 12.8 | 10.47 | |
ROIC | -0.31 | 0.22 | -0.26 | -0.32 | -0.62 | |
Return on tangible assets | -0.25 | -0.19 | -0.22 | -0.27 | -0.41 | |
Graham Net | -10.97 | -2.73 | -1.9 | -4.39 | -7.17 | |
Working capital | 5.55M | 13.09M | 10.3M | 5.22M | -1.22M | |
Tangible asset value | 5.86M | 11.41M | 8.35M | 3.54M | -2.1M | |
Net current asset value | -5.92M | 297K | -2.16M | -6.27M | -11.4M | |
Invested capital | 2.34 | 1.13 | 1.46 | 3.35 | -5.21 | |
Average receivables | 149K | 3.25M | 3.1M | 0 | 0 | |
Average payables | 1.09M | 1.11M | 993K | 716K | 650.5K | |
Average inventory | 106.5K | 358.5K | 252K | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.11 | -0.53 | -0.7 | -1.58 | 3.03 | |
Capex per share | 0.21 | 0 | 0 | 0 | 0 |
PYPD Frequently Asked Questions
What is PolyPid Ltd. stock symbol ?
PolyPid Ltd. is a IL stock and trading under the symbol PYPD
What is PolyPid Ltd. stock quote today ?
PolyPid Ltd. stock price is $4.6 today.
Is PolyPid Ltd. stock public?
Yes, PolyPid Ltd. is a publicly traded company.